Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

被引：1

作者：

Tannir, N. ^{[1
]}

Powles, T. ^{[2
]}

Motzer, R. J. ^{[3
]}

Rolland, F. ^{[4
]}

Gravis, G. ^{[5
]}

Staehler, M. ^{[6
]}

Rink, M. ^{[7
]}

Retz, M. ^{[8
]}

Csoszi, T. ^{[9
]}

McCaffrey, J. ^{[10
]}

De Giorgi, U. ^{[11
]}

Caserta, C. ^{[12
]}

Cheporov, S. ^{[13
]}

Esteban Gonzalez, E. ^{[14
]}

Duran, I. ^{[15
]}

Larkin, J. G. ^{[16
]}

Berg, W. ^{[17
]}

Clary, D. ^{[17
]}

Escudier, B. ^{[18
]}

Choueiri, T. K. ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med, London, England

[3] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[4] ICO Inst Cancerol Ouest Rene Gauducheau, Med Oncol, St Herblain, France

[5] Inst Paoli Calmettes, Med Outpatient, Urol, Marseille, France

[6] Maximilians Univ Munchen, Klinikum Ludwig, Urol, Munich, Germany

[7] Univ Med Ctr Hamburg Eppendorf, Urol, Hamburg, Germany

[8] Klinikum Rechts Isar Tech, Urol, Munich, Germany

[9] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Med Oncol & Hematol, Szolnok, Hungary

[10] Mater Private Hosp, Med Oncol, Oncol, Dublin, Ireland

[11] Ist Sci Romagnolo Studio & Cura Tumori, Med Oncol, Meldola, Italy

[12] Azienda Osped Sta Maria, Oncol, Terni, Italy

[13] Reg Clin Oncol Hosp, Clin Oncol, Yaroslavl, Russia

[14] Clinica, Oncol, Edificio Consultas Externas, Oviedo, Spain

[15] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[16] Royal Marsden Hosp NHS Fdn Trust, Med Oncol, London, England

[17] Exelixis Inc, Med Affairs, San Francisco, CA USA

[18] Inst Gustave Roussy, Immunotherapy & Innovat Therapy Unit, Villejuif, France

[19] Brigham & Womens Hosp, Dana Farber Canc Inst, Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw373.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

818P

引用

页数：1

共 50 条

[1] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
Mainwaring, Paul
Tannir, Nizar M.
Powles, Thomas
Motzer, Robert J.
Rolland, Frederic
Gravis, Gwanaelle
Staehler, Michael
Rink, Michael
Retz, Margitta
Csoszi, Tibor
McCaffrey, John A.
De Giorgi, Ugo
Caserta, Claudia
Cheporov, Sergey
Gonzalez, Emilio Esteban
Duran, Ignacio
Larkin, James G.
Berg, William
Clary, Douglas O.
Escudier, Bernard
Choueiri, Toni K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
[2] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
Donskov, Frede
Motzer, Robert J.
Voog, Eric
Hovey, Elizabeth J.
Grullich, Carsten
Nott, Louise M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[3] Analysis of overall survival (OS) based on early tumour shrinkage in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
Tan, T. H.
Duran, I.
Maroto, P.
Suarez, C.
Castellano, D.
Garcia del Muro, X.
Costa, L.
Martin-Couce, L.
Benzaghou, F.
Thomas, S.
Markby, D. W.
Choueiri, T. K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 186 - 186
[4] Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve in patients (pts) with advanced renal cell carcinoma (RCC).
Choueiri, Toni K.
Powles, Thomas
Escudier, Bernard J.
Tannir, Nizar M.
Mainwaring, Paul
Rini, Brian I.
Hammers, Hans J.
Donskov, Frede
Roth, Bruce J.
Peltola, Katriina
Lee, Jae-Lyun
Heng, Daniel Yick Chin
Schmidinger, Manuela
Aftab, Dana T.
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Pal, Sumanta K.
Hutson, Thomas E.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
Donskov, Frede
Motzer, Robert J.
Voog, Eric
Hovey, Elizabeth J.
Griillich, Carsten
Nott, Louise M.
Cuff, Katharine Ellen
Gil, Thierry
Jensen, Niels Viggo
Chevreau, Christine
Negrier, Sylvie
Depenbusch, Reinhard
Bergmann, Lothar
Cornelio, Izzy
Champsaur, Anne
Escudier, Bernard J.
Pal, Sumanta K.
Powles, Thomas
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
Bergmann, L.
Donskov, F.
Motzer, R. J.
Voog, E.
Hovey, E. J.
Gruellich, C.
Nott, L. M.
Cuff, K. E.
Gil, T.
Jensen, N., V
Chevreau, C.
Negrier, S.
Depenbusch, R.
Cornelio, I
Champsaur, A.
Escudier, B. J.
Pal, S. K.
Powles, T.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 201
[7] Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
Duran, Ignacio
Maroto, Pablo
Suarez, Cristina
Castellano, Daniel E.
Garcia del Muro, Xavier
Costa, Luis
Martin-Couce, Lidia
Benzaghou, Fawzi
Thomas, Stephane
Markby, David W.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[8] Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
Pal, Sumanta K.
Motzer, Robert J.
Fishman, Mayer N.
McDermott, Raymond S.
Passos-Coelho, Jose
Kopyltsov, Evgeniy
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[9] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Tannir, Nizar M.
Powles, Thomas
Escudier, Bernard J.
Donskov, Frede
Grunwald, Viktor
Sternberg, Cora N.
Schmidinger, Manuela
Schoffski, Patrick
Szczylik, Cezary
Peltola, Katriina Johanna
Nosov, Dmitry
Melichar, Bohuslav
Clary, Douglas O.
Scheffold, Christian
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
Schmidinger, M.
Tannir, N. M.
Powles, T.
Escudier, B. J.
Donskov, F.
Gruenwald, V
Sternberg, C. N.
Schoffski, P.
Szczylik, C.
Peltola, K. J.
Nosov, D.
Melichar, B.
Clary, D. O.
Scheffold, C.
Motzer, R. J.
Choueiri, T. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 200

← 1 2 3 4 5 →